- Home
- DDD vs ZURA Comparison
DDD vs ZURA Comparison
Compare DDD & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDD | ZURA |
|---|---|---|
| Founded | 1986 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.0M | 455.4M |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DDD | ZURA |
|---|---|---|
| Price | $3.30 | $5.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.75 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.6M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $386,902,000.00 | N/A |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $4.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $1.88 |
| 52 Week High | $4.12 | $7.25 |
Technical Indicators
Market Signals| Indicator | DDD | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 44.02 |
| Support Level | $3.10 | $5.22 |
| Resistance Level | $3.63 | $5.87 |
| Average True Range (ATR) | 0.17 | 0.43 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 38.38 | 3.54 |
Price Performance
Historical ComparisonAbout DDD 3D Systems Corporation
3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.